Market Update: Merck & Co Inc (NYSE:MRK) – U.S. FDA expands approval of Merck’s Keytruda to lung cancer

[Reuters] – The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with advanced non-small cell lung cancer, the most common form of the disease. The . . . → Read More: Market Update: Merck & Co Inc (NYSE:MRK) – U.S. FDA expands approval of Merck’s Keytruda to lung cancer Similar Articles: Stock Update (NYSE:MRK): Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: … Stock Update (NYSE:MRK): New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status Stock Update (NYSE:MRK): Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer